5 best RTSM platforms for MedTech and device clinical trials in 2026

A device trial with a registry arm, a post-market surveillance requirement, and a two-person clinical operations team doesn't need a randomization and trial supply management (RTSM) system built for a 40-country oncology program. It needs one a lean team can configure without a specialist IRT vendor's project queue standing between a protocol amendment and a live kit list. Viedoc's RTSM software is built into the same eClinical suite as your electronic data capture (EDC) database, so randomization and resupply run through one login rather than a separate interactive web response system, backed by 8,000-plus completed studies across 75-plus countries. This comparison reviews five RTSM platforms MedTech sponsors evaluate, across randomization flexibility, EDC integration, supply visibility, and audit readiness.

Your studies rarely look like a typical pharma trial. Registries, post-market surveillance protocols, and observational designs carry different randomization logic than a blinded drug study, and your clinical affairs lead is often also the person approving budget and fielding the audit. You need a system built for that reality, not retrofitted from a large pharma workflow.

Specialist interactive response technology (IRT) vendors built their platforms for complex, multi-arm drug trials, and that depth carries a configuration burden a lean device team rarely needs. Standalone systems also mean a second vendor relationship and a reconciliation step between randomization data and your case report forms. The platforms below are judged on fit: adaptable randomization design, direct EDC integration, real-time supply visibility, and audit evidence you can hand an auditor without assembling it from scratch.

Best RTSM solutions for MedTech and device trials: quick comparison

These five RTSM platforms represent the most evaluated options for MedTech and device sponsors, reviewed across randomization flexibility, EDC integration, supply visibility, and audit readiness.

1. Viedoc

Viedoc's RTSM software combines Viedoc Randomization and Viedoc Logistics inside the same eClinical suite as your EDC database, so your team runs randomization and resupply from the interface it already uses, rather than a separate interactive web response system. That single-platform design removes a reconciliation step lean device teams can't easily absorb. It supports both static, list-based randomization and dynamic, algorithm-driven assignment, so a registry and an adaptive post-market design can run on the same system.

For MedTech sponsors, the differentiator is fit rather than sheer scale. Viedoc's post-market surveillance software is a dedicated module for Japan PMDA-driven studies, a capability few RTSM-capable platforms built for the SMID market offer natively. Configurations can be updated throughout a study, and multiple randomization schemes can run within a single trial, which matters when a protocol adds a new arm after go-live.

On compliance, Viedoc's Trial Supply Management module supports FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, and Japan's APPI, and is ISO 27001 and SOC 2 certified, hosted on Microsoft Azure with 99.99% uptime. Role-based access and emergency unblinding restrict randomization data to authorized users, with support running 24/7 across global offices.

"Data handling, reviews, UAT, Query management and the monitoring is a walk in the park, which makes it stand out from other EDCs." – Deekshitha V., Mid Market

Verified proof points:

• Study scale: 8,000+ studies run on Viedoc across 75+ countries
• Integration: Randomization and supply management run within Viedoc EDC; no separate IWRS or IVRS login required
• Uptime and hosting: 99.99% platform uptime; hosted on Microsoft Azure
• Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, APPI (Japan); ISO 27001 and SOC 2 certified
• MedTech fit: Dedicated Japan post-market surveillance module
• Support: 24/7 support across global offices

2. Medidata

Medidata offers Medidata RTSM, a randomization and trial supply management system unified with Rave EDC on the Medidata Platform rather than run as a separate integration. The platform supports cohort management, multi-dose vial tracking, and an "Edit Live Design" capability that applies protocol updates without taking the system offline. Direct-to-patient shipments can be triggered at the site, visit, or patient level, with recipients confirming receipt through the myMedidata app. Medidata maintains a dedicated MedTech solutions track alongside its emerging biopharma and large biopharma segments, reflecting device and diagnostics trials as a distinct part of its customer base. The company positions Rave EDC and RTSM together as a single source of truth that removes the reconciliation step between randomization and case report form data.

3. Suvoda

Suvoda provides Suvoda RTSM, also referred to as interactive response technology (IRT), built to handle complex randomization, cohort management, and drug or device supply logistics. Its agentic AI capability is designed to shorten study kickoff to user acceptance testing, with an embedded AI assistant that surfaces depot inventory, supply risk, and compliance views through a conversational interface rather than a manually built report. Suvoda states its platform is purpose-built for complex protocols, with the bulk of its trial base concentrated in oncology, central nervous system (CNS), and rare disease studies rather than device-specific research. The company also offers direct-to-patient shipping tools and temperature excursion management for cold-chain supply, alongside systems integration services for sponsors running Suvoda alongside other eClinical vendors in a multi-vendor environment.

4. Almac Clinical Technologies

Almac Clinical Technologies, part of the Almac Group, offers IXRS3, an interactive response technology platform for patient randomization and clinical trial supply management. The system is available across two start-up modes that vary in customization level, speed to go live, and cost, letting sponsors choose a configuration that matches study complexity rather than defaulting to the most extensive build available. IXRS3 supports real-time, scientifically rigorous allocation methods designed to maintain balanced treatment assignment and blinding across simple to complex adaptive trial designs. Almac backs the platform with 24/7 global support from biostatisticians, language specialists, and system integration professionals, and the company reports coverage across more than 65 supported languages alongside a high volume of annual site activations globally each year.

5. Medrio

Medrio provides Medrio RTSM, a no-code randomization and trial supply management solution built to deploy without custom coding or a vendor programming queue. The platform automates dosing instructions, cohort assignment, randomization documentation, and site resupply alerts, with reported deployment in four to five weeks and mid-study updates completed in a week or less. Medrio RTSM integrates directly with Medrio's unified clinical data platform, sharing subject IDs, enrollment status, and supply data in real time to reduce reconciliation work between separate systems. The company maintains a dedicated MedTech industry track alongside its pharma and biotech and CRO tracks, and reports its platform has been used across tens of thousands of studies and sites spanning more than 30 countries worldwide, serving sponsors of varying sizes.

What to look for in RTSM solutions for MedTech and device trials

Device trials don't evaluate RTSM the way a large pharma sponsor does, and the criteria below reflect that.

Randomization design flexibility for non-drug study types

Registries, post-market observational studies, and adaptive device trials often need stratification logic that differs from a standard double-blind drug trial. A platform built primarily for pharma randomization schemes can force a device protocol into a workflow it wasn't designed for.

Best-in-class RTSM supports both static, list-based randomization and dynamic, algorithm-driven assignment within the same system, plus multiple schemes within a single trial, since device studies frequently add arms mid-study. Rigid, pharma-style templates turn a routine amendment into a change request rather than a configuration update.

Direct integration between RTSM and your EDC

A separate IWRS or IVRS login means a second system to train site staff on and a reconciliation step between randomization records and case report forms. That overhead compounds across every study in a lean team's portfolio.

The strongest RTSM platforms run inside the same login as electronic data capture, so randomizing and allocating supply happens without leaving the interface site staff already use daily. Audit trail data then lives in one place rather than being reconciled across two vendor systems at database lock.

Real-time supply visibility and automated resupply

Device studies frequently involve physical kits or consumables rather than a single investigational drug, and stockouts at a site can halt enrollment as effectively as a randomization failure. Site-specific inventory thresholds and expiration tracking need to run without a supply manager manually checking spreadsheets.

Look for a platform that processes supply actions in real time, with kits available as soon as they're registered as received, and automated alerts triggered by enrollment pace rather than fixed reorder dates.

Audit-ready compliance evidence for a lean QA function

MedTech companies often run clinical affairs and quality functions with less dedicated validation headcount than a large pharma sponsor, so an RTSM system's compliance posture directly affects your validation burden.

Best-in-class platforms carry certifications such as FDA 21 CFR Part 11, ISO 27001, and SOC 2, along with region-specific coverage, made available without a lengthy vendor audit request. If a sponsor runs studies subject to Japan's post-market surveillance requirements, native support for that pathway avoids bolting on a separate system later.

How to choose the right RTSM solution for MedTech and device trials

Matching your organization's profile to the right RTSM type matters more than ranking platforms on feature count.

Step 1: Define your study type and randomization complexity

Map out whether your near-term pipeline is dominated by registries, post-market observational studies, adaptive device trials, or a mix. A platform evaluated only against complex, multi-arm drug trial criteria may be over-engineered for a registry-heavy portfolio.

Step 2: Assess whether you need a standalone specialist vendor or an integrated suite

A dedicated IRT specialist can be the right fit for large, multi-region drug trials with complex adaptive designs. A lean device team running a mix of study types more often benefits from RTSM built directly into the same eClinical suite as EDC.

Step 3: Evaluate the support model against your internal headcount

Some vendors sell a highly configurable platform and expect your team to manage most of the configuration; others provide a consultative model that shares that load. If your clinical affairs lead also manages budget and audit prep, the support model matters as much as the feature set.

Step 4: Scrutinize region-specific regulatory requirements before you shortlist

If any part of your pipeline touches Japan's post-market surveillance requirements, confirm native support for it now rather than discovering the gap mid-study. Retrofitting that workflow onto a platform not built for it adds risk at the point you can least afford it.

Step 5: Choose a platform built for your team's size, not just your study's complexity

Once you know your study mix, support needs, and regulatory footprint, choose the platform that fits how your team actually works. Viedoc's RTSM software is built for exactly this profile, integrated into the same suite as EDC with no separate IWRS login, and you can book a demo to see how it handles your study design.

Frequently asked questions

What is the best RTSM platform for MedTech and device clinical trials?

Viedoc's RTSM software is the strongest fit for most MedTech and device sponsors, since randomization and trial supply management run inside the same login as electronic data capture rather than through a separate interactive web response system, backed by 8,000-plus completed studies and a dedicated Japan post-market surveillance module. Medidata is a strong alternative for sponsors already running large, complex trials on the Medidata Platform who need its cohort management and direct-to-patient capabilities. Suvoda suits sponsors running complex oncology, CNS, or rare disease protocols where its specialist IRT depth is the priority.

What should I look for when choosing an RTSM platform for a device trial?

Prioritize randomization flexibility for non-drug study types such as registries and post-market observational designs, direct EDC integration to avoid a second login and reconciliation step, real-time supply visibility for physical kits, and compliance evidence you can produce without a lengthy vendor audit request. A lean clinical affairs team also benefits more from a consultative vendor relationship than a platform that assumes in-house configuration expertise it doesn't have.

How long does it take to configure RTSM for a medical device study?

Configuration time depends on randomization complexity and whether the platform is integrated with your EDC or run as a separate system. Platforms built into the same eClinical suite as EDC avoid a second vendor onboarding process entirely, since the study team is already working inside a familiar Designer interface. Standalone IRT vendors typically require a dedicated project timeline before go-live, and complex, multi-arm adaptive designs generally take longer to configure than a straightforward registry or single-arm post-market study.

Which RTSM platforms support Japan post-market surveillance studies?

Native support for Japan's post-market surveillance requirements is uncommon among RTSM-capable platforms built for the small-to-mid-sized market. Viedoc includes a dedicated post-market surveillance module built for this pathway, while larger enterprise platforms typically require additional configuration or a regional service partner to support the same requirement. Confirming this capability before shortlisting matters most for sponsors already running or planning APAC device studies.

Do MedTech companies need a separate IRT vendor, or can RTSM run inside an EDC platform?

Many MedTech sponsors, particularly those running registries, observational studies, or a mix of smaller trials, are well served by RTSM built directly into their EDC platform, which removes a separate vendor relationship and reconciliation step. Sponsors running large, complex, multi-region drug trials with advanced adaptive designs more often need the depth of a dedicated IRT specialist. The right answer depends on study complexity and internal headcount rather than company size alone.

What is the difference between RTSM and a standalone IWRS or IVRS system?

Interactive web response systems (IWRS) and interactive voice response systems (IVRS) were the earlier technology used to manage patient randomization and drug supply, typically as standalone systems separate from EDC. RTSM (randomization and trial supply management) describes the modern version of that function, and on integrated platforms it runs directly inside the EDC system rather than as a separate login, removing the manual reconciliation step older IWRS and IVRS setups required.

Making the right RTSM choice for MedTech and device trials

The RTSM platforms MedTech sponsors evaluate span a wide range, from dedicated IRT specialists built for large, complex, multi-region drug trials to systems built directly into a broader eClinical suite. Both approaches solve the same core problem, accurate randomization and reliable supply, but they carry different overhead, vendor relationships, and configuration timelines.

Matching platform to organization matters more than feature count. A device sponsor running registries and post-market studies with a lean clinical affairs team typically weighs integration and support model most heavily, while a sponsor running large, complex, multi-arm trials may prioritize a specialist vendor's configuration depth. Geography matters too. Sponsors with Japan-market obligations weigh regional regulatory support alongside core randomization capability.

Switching RTSM vendors mid-portfolio carries real validation cost, and a mismatch between platform and study type compounds across every trial that follows. Choosing carefully at the outset, rather than retrofitting later, is worth the extra evaluation time up front.

Why Viedoc is the best RTSM choice for MedTech and device trials

For MedTech sponsors, the question isn't which RTSM platform has the deepest feature set. It's which one fits a lean team running non-standard study designs without a second vendor relationship. Viedoc's RTSM software answers that directly: randomization and supply management run inside the same login as your EDC database, with no separate IWRS or IVRS system to onboard site staff on.

That integration extends across the suite. Certified Designer training means your team amends randomization schemes without a vendor programming queue, and unlimited user seats keep costs predictable as your portfolio grows. Support runs 24/7 across global offices, and Viedoc's post-market surveillance module gives MedTech sponsors with Japan obligations a capability most SMID-focused platforms don't offer.

The compliance foundation holds up to audit scrutiny: ISO 27001 and SOC 2 certified, compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, and GAMP 5, hosted on Microsoft Azure with 99.99% uptime. Viedoc has run 8,000-plus studies across 75-plus countries since it began working in clinical research in 2003.

If you want an RTSM system built for how your device team actually works, without a second login, Viedoc is designed for exactly that. Book a demo or request a proposal and the team will walk through randomization design, supply visibility, and compliance evidence against your own study portfolio.